Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Stéphane Culine, Aude Fléchon et al.|Journal of Clinical Oncology|2024Cited by 18